<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35531958</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2379-3708</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>JCI insight</Title>
          <ISOAbbreviation>JCI Insight</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Endothelial PRMT5 plays a crucial role in angiogenesis after acute ischemic injury.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e152481</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1172/jci.insight.152481</ELocationID>
        <Abstract>
          <AbstractText>Arginine methylation mediated by protein arginine methyltransferases (PRMTs) has been shown to be an important posttranslational mechanism involved in various biological processes. Herein, we sought to investigate whether PRMT5, a major type II enzyme, is involved in pathological angiogenesis and, if so, to elucidate the molecular mechanism involved. Our results show that PRMT5 expression is significantly upregulated in ischemic tissues and hypoxic endothelial cells (ECs). Endothelial-specific Prmt5-KO mice were generated to define the role of PRMT5 in hindlimb ischemia-induced angiogenesis. We found that these mice exhibited impaired recovery of blood perfusion and motor function of the lower limbs, an impairment that was accompanied by decreased vascular density and increased necrosis as compared with their WT littermates. Furthermore, both pharmacological and genetic inhibition of PRMT5 significantly attenuated EC proliferation, migration, tube formation, and aortic ring sprouting. Mechanistically, we showed that inhibition of PRMT5 markedly attenuated hypoxia-induced factor 1-α (HIF-1α) protein stability and vascular endothelial growth factor-induced (VEGF-induced) signaling pathways in ECs. Our results provide compelling evidence demonstrating a crucial role of PRMT5 in hypoxia-induced angiogenesis and suggest that inhibition of PRMT5 may provide novel therapeutic strategies for the treatment of abnormal angiogenesis-related diseases, such as cancer and diabetic retinopathy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yi</LastName>
            <ForeName>Bing</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kazama</LastName>
            <ForeName>Kyosuke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Wennan</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Xiaobo</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Jianxin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>JCI Insight</MedlineTA>
        <NlmUniqueID>101676073</NlmUniqueID>
        <ISSNLinking>2379-3708</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>94ZLA3W45F</RegistryNumber>
          <NameOfSubstance UI="D001120">Arginine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.1.1.319</RegistryNumber>
          <NameOfSubstance UI="C498518">Prmt5 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.1.1.319</RegistryNumber>
          <NameOfSubstance UI="D011484">Protein-Arginine N-Methyltransferases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001120" MajorTopicYN="N">Arginine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042783" MajorTopicYN="Y">Endothelial Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018919" MajorTopicYN="Y">Neovascularization, Physiologic</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011484" MajorTopicYN="Y">Protein-Arginine N-Methyltransferases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Angiogenesis</Keyword>
        <Keyword MajorTopicYN="N">Hypoxia</Keyword>
        <Keyword MajorTopicYN="N">Signal transduction</Keyword>
        <Keyword MajorTopicYN="N">Vascular Biology</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35531958</ArticleId>
        <ArticleId IdType="pmc">PMC9090242</ArticleId>
        <ArticleId IdType="doi">10.1172/jci.insight.152481</ArticleId>
        <ArticleId IdType="pii">152481</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438(7070):932–936. doi: 10.1038/nature04478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature04478</ArticleId>
            <ArticleId IdType="pubmed">16355210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simons M. Angiogenesis: where do we stand now? Circulation. 2005;111(12):1556–1566. doi: 10.1161/01.CIR.0000159345.00591.8F.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.0000159345.00591.8F</ArticleId>
            <ArticleId IdType="pubmed">15795364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307. doi: 10.1038/nature10144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10144</ArticleId>
            <ArticleId IdType="pmc">PMC4049445</ArticleId>
            <ArticleId IdType="pubmed">21593862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27–31. doi: 10.1038/nm0195-27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0195-27</ArticleId>
            <ArticleId IdType="pubmed">7584949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9(6):677–684. doi: 10.1038/nm0603-677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0603-677</ArticleId>
            <ArticleId IdType="pubmed">12778166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivan M, et al.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464–468. doi: 10.1126/science.1059817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1059817</ArticleId>
            <ArticleId IdType="pubmed">11292862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaakkola P, et al.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–472. doi: 10.1126/science.1059796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1059796</ArticleId>
            <ArticleId IdType="pubmed">11292861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stanislawski M, Mitard M. Expression of immunoglobulin variable region antigens on mouse B lymphocytes. J Immunol. 1979;122(3):1045–1053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">312814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richard DE, et al.  p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem. 1999;274(46):32631–32637. doi: 10.1074/jbc.274.46.32631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.274.46.32631</ArticleId>
            <ArticleId IdType="pubmed">10551817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong JW, et al.  Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 2002;111(5):709–720. doi: 10.1016/S0092-8674(02)01085-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(02)01085-1</ArticleId>
            <ArticleId IdType="pubmed">12464182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng J, et al.  SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell. 2007;131(3):584–595. doi: 10.1016/j.cell.2007.08.045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.08.045</ArticleId>
            <ArticleId IdType="pmc">PMC2128732</ArticleId>
            <ArticleId IdType="pubmed">17981124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pahlich S, et al.  Protein arginine methylation: cellular functions and methods of analysis. Biochim Biophys Acta. 2006;1764(12):1890–1903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17010682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why. Mol Cell. 2009;33(1):1–13. doi: 10.1016/j.molcel.2008.12.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2008.12.013</ArticleId>
            <ArticleId IdType="pmc">PMC3372459</ArticleId>
            <ArticleId IdType="pubmed">19150423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanc RS, Richard S. Arginine methylation: the coming of age. Mol Cell. 2017;65(1):8–24. doi: 10.1016/j.molcel.2016.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2016.11.003</ArticleId>
            <ArticleId IdType="pubmed">28061334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gary JD, Clarke S. RNA and protein interactions modulated by protein arginine methylation. Prog Nucleic Acid Res Mol Biol. 1998;61:65–131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9752719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim MS, et al.  A draft map of the human proteome. Nature. 2014;509(7502):575–581. doi: 10.1038/nature13302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13302</ArticleId>
            <ArticleId IdType="pmc">PMC4403737</ArticleId>
            <ArticleId IdType="pubmed">24870542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tee WW, et al.  Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency. Genes Dev. 2010;24(24):2772–2777. doi: 10.1101/gad.606110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.606110</ArticleId>
            <ArticleId IdType="pmc">PMC3003195</ArticleId>
            <ArticleId IdType="pubmed">21159818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim H, Ronai ZA. PRMT5 function and targeting in cancer. Cell Stress. 2020;4(8):199–215. doi: 10.15698/cst2020.08.228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15698/cst2020.08.228</ArticleId>
            <ArticleId IdType="pmc">PMC7380451</ArticleId>
            <ArticleId IdType="pubmed">32743345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stopa N, et al.  The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cell Mol Life Sci. 2015;72(11):2041–2059. doi: 10.1007/s00018-015-1847-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-015-1847-9</ArticleId>
            <ArticleId IdType="pmc">PMC4430368</ArticleId>
            <ArticleId IdType="pubmed">25662273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lattouf H, et al.  PRMT5 prognostic value in cancer. Oncotarget. 2019;10(34):3151–3153. doi: 10.18632/oncotarget.26883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.26883</ArticleId>
            <ArticleId IdType="pmc">PMC6516714</ArticleId>
            <ArticleId IdType="pubmed">31139329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarrold J, Davies CC. PRMTs and arginine methylation: cancer’s best-kept secret? Trends Mol Med. 2019;25(11):993–1009. doi: 10.1016/j.molmed.2019.05.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2019.05.007</ArticleId>
            <ArticleId IdType="pubmed">31230909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Copeland RA. Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery. Philos Trans R Soc Lond B Biol Sci. 2018;373(1748):20170080.  doi: 10.1098/rstb.2017.0080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1098/rstb.2017.0080</ArticleId>
            <ArticleId IdType="pmc">PMC5915721</ArticleId>
            <ArticleId IdType="pubmed">29685962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan-Penebre E, et al.  A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015;11(6):432–437. doi: 10.1038/nchembio.1810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio.1810</ArticleId>
            <ArticleId IdType="pubmed">25915199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, et al.  A patent review of arginine methyltransferase inhibitors (2010-2018) Expert Opin Ther Pat. 2019;29(2):97–114. doi: 10.1080/13543776.2019.1567711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13543776.2019.1567711</ArticleId>
            <ArticleId IdType="pubmed">30640571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gullà A, et al.  Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 2018;32(4):996–1002. doi: 10.1038/leu.2017.334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/leu.2017.334</ArticleId>
            <ArticleId IdType="pmc">PMC5871539</ArticleId>
            <ArticleId IdType="pubmed">29158558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vinet M, et al.  Protein arginine methyltransferase 5: a novel therapeutic target for triple-negative breast cancers. Cancer Med. 2019;8(5):2414–2428. doi: 10.1002/cam4.2114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.2114</ArticleId>
            <ArticleId IdType="pmc">PMC6537044</ArticleId>
            <ArticleId IdType="pubmed">30957988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, et al.  EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma. Exp Eye Res. 2021;202:108286.  doi: 10.1016/j.exer.2020.108286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.exer.2020.108286</ArticleId>
            <ArticleId IdType="pubmed">33035554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kocherova I, et al.  Human umbilical vein endothelial cells (HUVECs) co-culture with osteogenic cells: from molecular communication to engineering prevascularised bone grafts. J Clin Med. 2019;8(10):1602.  doi: 10.3390/jcm8101602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm8101602</ArticleId>
            <ArticleId IdType="pmc">PMC6832897</ArticleId>
            <ArticleId IdType="pubmed">31623330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KS, et al.  A novel role of hypoxia-inducible factor in cobalt chloride- and hypoxia-mediated expression of IL-8 chemokine in human endothelial cells. J Immunol. 2006;177(10):7211–7224. doi: 10.4049/jimmunol.177.10.7211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.177.10.7211</ArticleId>
            <ArticleId IdType="pubmed">17082639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Limbourg A, et al.  Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat Protoc. 2009;4(12):1737–1746. doi: 10.1038/nprot.2009.185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nprot.2009.185</ArticleId>
            <ArticleId IdType="pubmed">19893509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JJ, et al.  Systematic interrogation of angiogenesis in the ischemic mouse hind limb: vulnerabilities and quality assurance. Arterioscler Thromb Vasc Biol. 2020;40(10):2454–2467. doi: 10.1161/ATVBAHA.120.315028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/ATVBAHA.120.315028</ArticleId>
            <ArticleId IdType="pmc">PMC7505144</ArticleId>
            <ArticleId IdType="pubmed">32787524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benndorf RA, et al.  Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A(2) receptor: a potential link between oxidative stress and impaired angiogenesis. Circ Res. 2008;103(9):1037–1046. doi: 10.1161/CIRCRESAHA.108.184036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.108.184036</ArticleId>
            <ArticleId IdType="pubmed">18802021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tousoulis D, et al.  The role of nitric oxide on endothelial function. Curr Vasc Pharmacol. 2012;10(1):4–18. doi: 10.2174/157016112798829760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/157016112798829760</ArticleId>
            <ArticleId IdType="pubmed">22112350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 2005;6(2):209.  doi: 10.1186/gb-2005-6-2-209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/gb-2005-6-2-209</ArticleId>
            <ArticleId IdType="pmc">PMC551528</ArticleId>
            <ArticleId IdType="pubmed">15693956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abhinand CS, et al.  VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J Cell Commun Signal. 2016;10(4):347–354. doi: 10.1007/s12079-016-0352-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12079-016-0352-8</ArticleId>
            <ArticleId IdType="pmc">PMC5143324</ArticleId>
            <ArticleId IdType="pubmed">27619687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin C, et al.  Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res. 2004;22(6):1175–1181. doi: 10.1016/j.orthres.2004.03.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.orthres.2004.03.002</ArticleId>
            <ArticleId IdType="pubmed">15475194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karkhanis V, et al.  Versatility of PRMT5-induced methylation in growth control and development. Trends Biochem Sci. 2011;36(12):633–641. doi: 10.1016/j.tibs.2011.09.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2011.09.001</ArticleId>
            <ArticleId IdType="pmc">PMC3225484</ArticleId>
            <ArticleId IdType="pubmed">21975038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gkountela S, et al.  PRMT5 is required for human embryonic stem cell proliferation but not pluripotency. Stem Cell Rev Rep. 2014;10(2):230–239. doi: 10.1007/s12015-013-9490-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12015-013-9490-z</ArticleId>
            <ArticleId IdType="pmc">PMC3972323</ArticleId>
            <ArticleId IdType="pubmed">24477620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paul C, et al.  The histone- and PRMT5-associated protein COPR5 is required for myogenic differentiation. Cell Death Differ. 2012;19(5):900–908. doi: 10.1038/cdd.2011.193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2011.193</ArticleId>
            <ArticleId IdType="pmc">PMC3321631</ArticleId>
            <ArticleId IdType="pubmed">22193545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, et al.  Prmt5 is required for germ cell survival during spermatogenesis in mice. Sci Rep. 2015;5:11031.  doi: 10.1038/srep11031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep11031</ArticleId>
            <ArticleId IdType="pmc">PMC4466585</ArticleId>
            <ArticleId IdType="pubmed">26072710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanade SR, Eckert RL. Protein arginine methyltransferase 5 (PRMT5) signaling suppresses protein kinase Cδ- and p38δ-dependent signaling and keratinocyte differentiation. J Biol Chem. 2012;287(10):7313–7323. doi: 10.1074/jbc.M111.331660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.331660</ArticleId>
            <ArticleId IdType="pmc">PMC3293539</ArticleId>
            <ArticleId IdType="pubmed">22199349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholas C, et al.  PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.) PLoS One. 2013;8(9):e74710.  doi: 10.1371/journal.pone.0074710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0074710</ArticleId>
            <ArticleId IdType="pmc">PMC3786975</ArticleId>
            <ArticleId IdType="pubmed">24098663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim H, et al.  PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity. Sci Transl Med. 2020;12(551):eaaz5683.  doi: 10.1126/scitranslmed.aaz5683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaz5683</ArticleId>
            <ArticleId IdType="pmc">PMC7508354</ArticleId>
            <ArticleId IdType="pubmed">32641491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, et al.  PRMT5 promotes human lung cancer cell apoptosis via Akt/Gsk3β signaling induced by resveratrol. Cell Transplant. 2019;28(12):1664–1673. doi: 10.1177/0963689719885083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0963689719885083</ArticleId>
            <ArticleId IdType="pmc">PMC6923546</ArticleId>
            <ArticleId IdType="pubmed">31665911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jing P, et al.  Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling. Cancer Lett. 2018;427:38–48. doi: 10.1016/j.canlet.2018.04.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2018.04.019</ArticleId>
            <ArticleId IdType="pubmed">29679612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen M, et al.  Inhibition of cardiomyocyte hypertrophy by protein arginine methyltransferase 5. J Biol Chem. 2014;289(35):24325–24335. doi: 10.1074/jbc.M114.577494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M114.577494</ArticleId>
            <ArticleId IdType="pmc">PMC4148861</ArticleId>
            <ArticleId IdType="pubmed">25012667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris DP, et al.  Tumor necrosis factor (TNF)-α induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-κB p65 methylation. J Biol Chem. 2014;289(22):15328–15339. doi: 10.1074/jbc.M114.547349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M114.547349</ArticleId>
            <ArticleId IdType="pmc">PMC4140890</ArticleId>
            <ArticleId IdType="pubmed">24753255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris DP, et al.  PRMT5-mediated methylation of NF-κB p65 at Arg174 is required for endothelial CXCL11 gene induction in response to TNF-α and IFN-γ costimulation. PLoS One. 2016;11(2):e0148905.  doi: 10.1371/journal.pone.0148905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0148905</ArticleId>
            <ArticleId IdType="pmc">PMC4768879</ArticleId>
            <ArticleId IdType="pubmed">26901772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandyopadhyay S, et al.  HOXA9 methylation by PRMT5 is essential for endothelial cell expression of leukocyte adhesion molecules. Mol Cell Biol. 2012;32(7):1202–1213. doi: 10.1128/MCB.05977-11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.05977-11</ArticleId>
            <ArticleId IdType="pmc">PMC3302442</ArticleId>
            <ArticleId IdType="pubmed">22269951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quillien A, et al.  Prmt5 promotes vascular morphogenesis independently of its methyltransferase activity. PLoS Genet. 2021;17(6):e1009641.  doi: 10.1371/journal.pgen.1009641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pgen.1009641</ArticleId>
            <ArticleId IdType="pmc">PMC8248709</ArticleId>
            <ArticleId IdType="pubmed">34153034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Q, et al.  The Cdh5-CreERT2 transgene causes conditional Shb gene deletion in hematopoietic cells with consequences for immune cell responses to tumors. Sci Rep. 2019;9(1):7548.  doi: 10.1038/s41598-019-44039-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-44039-z</ArticleId>
            <ArticleId IdType="pmc">PMC6525206</ArticleId>
            <ArticleId IdType="pubmed">31101877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apte RS, et al.  VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–1264. doi: 10.1016/j.cell.2019.01.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2019.01.021</ArticleId>
            <ArticleId IdType="pmc">PMC6410740</ArticleId>
            <ArticleId IdType="pubmed">30849371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan Y, et al.  PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3β signaling cascades. Aging (Albany NY) 2021;13(3):4468–4481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7906165</ArticleId>
            <ArticleId IdType="pubmed">33495409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu JM, et al.  Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat Cell Biol. 2011;13(2):174–181. doi: 10.1038/ncb2158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2158</ArticleId>
            <ArticleId IdType="pmc">PMC3048027</ArticleId>
            <ArticleId IdType="pubmed">21258366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avila MA, et al.  Regulation by hypoxia of methionine adenosyltransferase activity and gene expression in rat hepatocytes. Gastroenterology. 1998;114(2):364–371. doi: 10.1016/S0016-5085(98)70489-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0016-5085(98)70489-5</ArticleId>
            <ArticleId IdType="pubmed">9453498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yildirim AO, et al.  Increased protein arginine methylation in chronic hypoxia: role of protein arginine methyltransferases. Am J Respir Cell Mol Biol. 2006;35(4):436–443. doi: 10.1165/rcmb.2006-0097OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2006-0097OC</ArticleId>
            <ArticleId IdType="pubmed">16690984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lafleur VN, et al.  Transcriptional repression of hypoxia-inducible factor-1 (HIF-1) by the protein arginine methyltransferase PRMT1. Mol Biol Cell. 2014;25(6):925–935. doi: 10.1091/mbc.e13-07-0423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1091/mbc.e13-07-0423</ArticleId>
            <ArticleId IdType="pmc">PMC3952860</ArticleId>
            <ArticleId IdType="pubmed">24451260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan Y, Nie H. Protein arginine methyltransferase 5: a potential cancer therapeutic target. Cell Oncol (Dordr) 2021;44(1):33–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33469838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu F, et al.  Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis. J Clin Invest. 2015;125(9):3532–3544. doi: 10.1172/JCI81749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI81749</ArticleId>
            <ArticleId IdType="pmc">PMC4588241</ArticleId>
            <ArticleId IdType="pubmed">26258414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, et al.  Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature. 2010;465(7297):483–486. doi: 10.1038/nature09002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature09002</ArticleId>
            <ArticleId IdType="pubmed">20445537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong QG, et al.  A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol. 1997;17(8):1599–1604. doi: 10.1161/01.ATV.17.8.1599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.ATV.17.8.1599</ArticleId>
            <ArticleId IdType="pubmed">9301641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brenes RA, et al.  Toward a mouse model of hind limb ischemia to test therapeutic angiogenesis. J Vasc Surg. 2012;56(6):1669–1679. doi: 10.1016/j.jvs.2012.04.067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jvs.2012.04.067</ArticleId>
            <ArticleId IdType="pmc">PMC3508332</ArticleId>
            <ArticleId IdType="pubmed">22836102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kastana P, et al.  Matrigel plug assay for in vivo evaluation of angiogenesis. Methods Mol Biol. 2019;1952:219–232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30825178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker M, et al.  Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc. 2011;7(1):89–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22193302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnaoutova I, et al.  The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis. 2009;12(3):267–274. doi: 10.1007/s10456-009-9146-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10456-009-9146-4</ArticleId>
            <ArticleId IdType="pubmed">19399631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang CC, et al.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2(2):329–333. doi: 10.1038/nprot.2007.30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nprot.2007.30</ArticleId>
            <ArticleId IdType="pubmed">17406593</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
